Decreased numerical density of pericapillary oligodendrocytes in the cortex in schizophrenia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 12, 2007, Pages 58-65

  Vostrikov, V M ^a  

^a NONE

Author keywords

Glia; Neuroanatomy; Pericapillary oligodendrocytes; Schizophrenia

Indexed keywords

EID: 38949156172     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Abbott N.J., Ronnback L., Hansson E.J. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
9. Ambrosi G., Virgintino D., Benagiano V. et al. Glial cells and blood-brain barrier in the human cerebral cortex. Ital J Anat Embryol 1995; 100: 177-184.
10. Andreasen N. C. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiat 1982; 39: 784-788.
11. Andreasen N. C., Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiat 1982; 39: 789-794.
12. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 2002; 27: 672-683.
13. Bartzokis G., Nuechterlein K.H., Lu P.H. et al. Dysregulated brain development in adult men with schizophrenia: A magnetic resonance imaging study. Biol Psychiat 2003; 53: 412-421.
14. Beggah A. T., Dours-Zimmermann M. T., Barras P.M. et al. Lesion-in-duced differential expression and cell association of Neurocan, Brevican, Versican VI and V2 in the mouse dorsal root entry zone. Neuroscience 2005; 133:749-762.
15. Bella-Morales R., Fedetz M., Alcina A. et al. High susceptibility of a human oligodendroglial cell line to herpes simplex type 1 infection. J Neurovirol 2005; 11: 190-198.
16. Bernardo A., Greco A., Levi G. et al. Differential lipid peroxidation, Mn Superoxide, and bcl-2 expression contribute to the maturation-dependent vulnerability of oligodendrocytes to oxidative stress. J Neuropathol Exp Neurol 2003; 62: 509-519.
17. Bieber A.J., Warrington A., Pease L.R. et al. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001; 24: 39-44.
18. Burdo J.R., Martin J., Menzies S.L. et al. Cellular distribution of iron in the brain of the Belgrade rat. Neuroscience 1999; 93: 1189-1196.
19. Byne W., Kidkardnee S., Tatusov A. et al. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 2006; 85: 245-253.
20. Casaccia-Bonnefil P. Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in development and disease. Glia 2000; 29: 124-135.
21. Cid C., Garcia-Villanueva M., Salinas M. et al. Detection of anti-heat shock protein 90 beta (Hsp90beta) antibodies in cerebrospinal fluid. J Immunol Methods 2007; 318: 153-157.
22. lose A.C., Dimcheff D.E., Favara C. et al. Oligodendrocytes are a major target of the toxicity of spongiogenic murine retroviruses. Am J Pathol 2006; 169: 1026-1038.
23. Cunningham L.A., Wetzel M., Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-339.
24. Davis J.M. Dose equivalence of the antipsychotic drugs. J Psychiat Res 1974; 11: 65-69.
25. Davis K.L., Stewart D.G., Friedman J.I. et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiat 2003; 60: 443-456.
26. Dean B., Laws S.M., Hone E. et al. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiat 2003; 54: 616-622.
27. Descamps L., Coisne C., Dehouck B. et al. Protective effect of glial cells against lipopolysaccharide-mediated blood-brain barrier injury. Glia 2003; 42: 46-58.
28. Fendri C., Mechri A., Khiari G. et al. Implication du stress oxydant dans la physiopathologie de la schizophrenic: revue de la literature. Encephale 2006; 32: 244-252.
29. Garcia C.I., Paez P., Soto E.F. et al. Differential effects of apotransferrin on two populations of oligodendroglial cells. Glia 2003; 42: 406-416.
30. Garwood J., Gardon E., Dobbertin A. et al. The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor. Eur J Neurosci 2004; 20: 2524-2540.
31. Gundersen H.J., Jensen E. B. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147: 229-263.
32. Hakak Y., Walker J.R., Li C. et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
33. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflamatory-vascular synthesis. BMC Med Genetics 2005; 6: 7. http:/ /www.biomedcentral.eom/1471-2350/6/7
34. Haorah J., Ramirez S.H., Schall K. et al. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem 2007; 101: 566-576.
35. Hof P.R., Haroutunian V., Friedrich V.L. et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiat 2003; 53: 1075-1085.
36. Hofmann M., Seifritz E., Botschev C. et al. Serum iron and ferritin in acute neuroleptic akathasia. Psychiat Res 2000; 93: 201-207.
37. Hu C.Y., Ong W.Y., Sundaram R.K. et al. Immunocytochemical localization of apolipoprotein D in oligodendrocyte precursor-like cells, perivascular cells, and pericytes in the human cerebral cortex. J Neurocytol 2001; 30: 209-218.
38. Jernigan T.L., Trauner D.A., Hesselink J. R. et al. Maturation of human cerebrum observed in vivo during adolescence. Brain 1991; 114: 2037-2049.
39. Johansson B.B. The physiology of the blood-brain barrier. Adv Exp Med Biol 1990; 274: 25-39.
40. Kacem K., Locombe P., Seylaz J. et al. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter; a confocal microscopy study. Glia 1998; 23: 1-10.
41. Kamada H., Yu F., Nito C. et al. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke 2007; 38: 1044-1049.
42. Kim G. W., Gasche Y., Grzeschik S. et al. Neurodegeneration in striaturn induced by the mitochondrial toxin 3-nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption? J Neurosci 2003; 23: 8733-8742.
43. Kim J.H., Kim J.H., Park J.A. et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006; 39: 339-345.
44. Kong G.Y., Kristensson K., Bentivoglio M. Reaction of mouse brain oligodendrocytes and their precursors, astrocytes and microglia, to proinflammatory mediators circulating in the cerebrospinal fluid. Glia 2002; 37: 191-205.
45. Kreczmanski P., Schmidt-Kastner R., Heinsen H. et al. Stereological studies of capillary length density in the frontal cortex of schizophrenics. Acta Neuropathol (Berl) 2005; 109: 510-518.
46. Lahti A.C., Holcomb H.H., Medoff D.R. et al. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiat 2001; 158: 1797-1808.
47. Lahti A.C., Weiler M.A., Holcomb H.H. et al. Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology 2006; 31: 221-230.
48. Larsen P.H., Yong V. W. The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J Neurosci 2004; 24: 7597-7603.
49. Ling E.A., Leblond C.P. Investigation of glial cells in semithin sections. II. Variation with age in the numbers of the various glial cell types in rat cortex and copus callosum. J Comp Neurol 1973; 149: 73-82.
50. Mahadik S.P., Khan M.M., Evans D.R. et al. Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophr Res 2002; 58: 55-62.
51. Michel TM., Thome J., Martin D. et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 2004; 111: 1191-1201.
52. Moos T., Oates P.S., Morgan E.H. Expression of transferrin mRNA in rat oligodendrocytes is iron-independent and changes with increasing age. Nutr Neurosci 2001; 4: 15-23.
53. Muller N., Riedel M., Hadjamu M. et al. Increase in expression of adhesion molecule receptors on T helper cells during anti psychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiat 1999; 156: 634-636.
54. Navarro A., Del Valle E., Tolivia J. Differential expression of apolipoprotein d in human astroglial and oligodendroglial cells. J Histochem Cytochem 2004; 52: 1031-1036.
55. Ohnuma T., Augood S.J., Arai H. et al. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998; 56: 207-217.
56. Orlovskaya D.D., Vostrikov V.M., Rachmanova V.I. et al. Decreased numerical density of oligodendroglial cells in postmortem prefrontal cortex in schizophrenia, bipolar affective disorder, and major depression. Schizophr Res 2000; 41: 105-106. (Abstract).
57. Pesheva P., Gloor S., Schachner M. et al. Tenascin-R is an intrinsic autocrine factor for oligodendrocyte differentiation and promotes cell adhesion by a sulfatide-mediated mechanism. J Neurosci 1997; 17: 4642-4651.
58. Peters A., Selhares C. Oligodendrocytes, their progenitors and other neuronal cells in the aging primate cerebral cortex. Cereb Cortex 2004; 14: 995-1007.
59. Pitt D., Nagelmeier I.E., Wilson H.C. et al. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003; 61: 1113-1120.
60. Polak M., Haymaker W., Johnson I.E. et al. Neuroglia and their reactions. In: W. Haymaker, R.D. Adams (eds.). Hitology and Histopathology of th Nervous System. Charles C. Tomas Publisher, Springfield 1982; 363-480.
61. Potkin S.G., Alva G., Fleming K. et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiat 2002; 159: 227-237.
62. Ragland J.D., Gur R.C., Raz J. et al. Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study. Am J Psychiat 2001; 158: 1114-1125.
63. Schmitt A., Asan E., Lesch K.P. et al. A splice variant of glutamate transporter GLT1/EAAT2 expressed in neurons: cloning and localization in rat nervous system. Neuroscience 2002; 109: 45-61.
64. Schultz S.K., O'Leary D.S., Boles Ponto L.L. et al. Age and regional cerebral blood flow in schizophrenia: age effects in anterior cingulate, frontal, and parietal cortex. J Neuropsychiat Clin Neurosci 2002; 14: 19-24.
65. Senitz D., Winkelmann E. Neuronal strukturanormalitat im orbitofrontalen cortex bei Schizophrenien. J Hirnforsch 1991; 32: 149-158.
66. Sole S., Petegnief V., Gorina R. et al. Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 2004; 63: 338-349.
67. Spoerri P.E., Spoerri O., Glees P. Reacting ultrastructure of the human oligodendrocyte (a study of cerebral cortex distant to brain tumours). Acta Neurochir (Wien) 1979; 46: 45-52.
68. Uranova N., Orlovskaya D., Vikhreva O. et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597-610.
69. Uranova N.A., Vostrikov V.M., Orlovskaya D.D. et al. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269-275.
70. Uranova N.A., Vostrikov V.M., Vikhreva O.V. et al. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007; 1-9.
71. Vostrikov V.M., Uranova N.A., Vikhreva O.V. et al. The role of oligodendrocyte pathology in schizophrenia. Schizophr Bul 2007; 31: 2: 272-273.
72. Wolkin A., Angrist B., Wolf A. et al. Low frontal glucose utilization in chronic schizophrenia: a replication study. Am J Psychiat 1988; 145: 251-253.
73. Yakovlev P.L., Lecours A.R. The myelogenetic cycles of regional brain maturation of the brain. In: A. Minkowski (ed.). Regional Development of the Brain in Early Life, Blackwell. Oxford 1967; 3-70.
74. Yanik M., Kocyigit A., Tutkun H. et al. Plasma manganese, selenium, zinc, cooper, and iron concentration in patients with schizophrenia. Biol Trace Elem Res 2004; 98: 109-117.
75. Yao J.K., Leonard S., Ready R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004; 30: 923-934.
76. Yao J.K., Leonard S., Ready R. Altered glutathione redox state in schizophrenia. Dis Markers 2006; 22: 83-93.
77. Yokoo H., Nobusawa S., Takebayashi H. et al. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol 2004; 164: 1717-1725.